CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

A new review from the Cochrane Database of Systematic Reviews confirms that antidepressants can effectively reduce symptoms of generalized anxiety disorder (GAD) in clinical trials. However, there is ...

Learn about the gut-brain connection in mental health and how targeting serotonin in the gut could revolutionise ...

A new Cochrane review confirms that antidepressants effectively reduce symptoms of generalized anxiety disorder (GAD) under trial conditions, although there is limited data on long-term usage.